From bedside to breakthroughs: Reimagining the human experience in healthcare

Something is broken in the way pharma supports patients. Programmes are built, budgets are allocated, and patient centricity is named as a priority in every strategic plan. Yet, patients still fall through the cracks. They still navigate a fragmented system largely on their own. They still ration doses, miss appointments, and abandon therapies that were working – not because they do not want to get better, but because the infrastructure meant to support them was not designed around the reality of their lives.

I spent my early career at Brigham and Women's Hospital, training as a clinical pharmacist in a transplant unit and on emergency consults. What that environment taught me is that patients arrive carrying years of history. By the time someone reached me, they had often been on a diagnostic journey for years – misdiagnosed, undertreated, cycling through a system built around clinical workflows and institutional efficiency, rather than the human being at the centre of it. Watching that up close gave me a very specific definition of what it means to truly support a patient. It is not enough to have a programme. The programme must work for the person, in the context of their real life, with all its complexity and competing demands.

The shift from patient-centric to human-centric thinking

That experience is what drives my conviction that the industry needs to move beyond patient-centric thinking toward something more honest: human-centric design. The distinction matters. Patient-centric programmes define people through the lens of their disease and ask how we better serve them in their role as a patient. Human-centric programmes ask a broader and harder question – who is this person, and what does health mean in the full context of their life? A person managing a chronic condition is also a parent, an employee, a caregiver, someone carrying financial pressure and personal ambition alongside their diagnosis. The moment a programme is designed only around the clinical journey, it has already missed the most important parts of what that person is navigating every day.

In practice, that shift shows up in three places:

The first is where insight begins: human-centric organisations go upstream, into people's homes and communities and daily routines, to understand what a good day looks like for someone managing their condition and what gets in the way of it.

The second is how programmes are designed: accounting for the emotional weight of a diagnosis, the logistical burden on a family member, the financial anxiety that makes someone ration a dose, the stigma that keeps them from filling a prescription.

The third is measurement: asking whether we are reducing burden on the full support system, reaching the people who most need the intervention, and improving quality of life in ways the person themselves would recognise. That requires new metrics, and the organisational courage to report against them honestly.

What gets lost when functions stay siloed

Building a patient excellence organisation that unites patient support, field reimbursement, clinical education, advocacy, and patient experience is fundamentally a cultural and philosophical challenge – and many companies underestimate that. When those functions operate independently, each one will tell you it is patient-focused, and each one probably is, within its own frame. The result is different parts of the organization, each holding one piece of the patient's reality, with no one responsible for the whole.

What gets lost in that model is the person. When a patient speaks with a clinical educator who has no visibility into a reimbursement challenge that has been unresolved for three weeks, or no connection to the advocacy resources that could provide community support, the experience fragments. The patient ends up carrying the connective tissue between functions that should be carrying it themselves. Each function reports against its own metrics, hits its own goals, and the gap between them – which is where people struggle – belongs to no one.

Uniting these functions requires a shared definition of success that none of them can achieve alone. That means anchoring everything to the lived experience of navigating a serious condition while trying to maintain a life. When that is the organising principle, the boundaries between functions become obstacles worth dismantling. Field reimbursement, clinical education, and advocacy are one interconnected system, each one shaping the patient's experience of the whole. Shared accountability, through joint planning, shared metrics, and forums where friction gets surfaced and resolved, is what holds it together.

Integrating AI without losing the human connection

The approach that makes the most sense is to start where the quality case for AI is clearest: highly manual, administrative functions where the variability introduced by human-to-human-to-human execution creates quality problems. Deploying AI to handle that work frees the people in these organisations to focus on the part that technology cannot replicate: the empathetic, real-time, human-facing support that a person managing a difficult condition needs.

The goal is AI as the connective tissue of the healthcare ecosystem, linking disconnected data, smoothing the handoffs between providers, pharmacies, insurance companies, and patients, identifying where someone is getting stuck before they disappear from the system.

Today, too much of that journey involves faxed prescriptions, unanswered phone calls, and information gaps that leave a patient navigating alone. Getting the infrastructure right means the humans in our programmes can spend their time on what matters most.

Patient experience as a long-term investment in health outcomes

The conversations about patient experience investment tend to go the wrong direction when budgets tighten. When that happens, a framing that works centres on what the cost of the gap is for the patient. When someone has been on a diagnostic journey for years and finally has a treatment that works, the question is whether the system around them is designed to keep them on it. Adherence is rooted in experience. The financial anxiety, the logistical friction, the moments where the system is confusing or unresponsive – those are where people fall out, and their outcomes suffer.

Programmes that support long-term engagement improve outcomes. The contribution to sustained health in a population of people who have already waited a long time for good options is the measure that matters. The most powerful thing we can do is design programmes people want to engage with, built around real human motivation. That means involving patients in the design process from the beginning, as co-creators with full influence over the outcome. When you do that, the programmes you build are more coherent, more useful, and more worthy of the trust people place in them. That is what pharma is here to deliver.

About the author

Deborah Reardon is vice president of patient excellence at Boehringer Ingelheim, where she embeds the patient voice into every stage of drug development and commercialisation. She built her career on a rare combination of clinical and strategic experience, starting as a clinical pharmacy specialist at Brigham and Women's Hospital, where she served as lead pharmacist on the world's first face and hand transplant.